Abstract S120 Figure 1 Comparison of biological function of murine (m) GM-CSF produced after lentiviral-gene transfer and purchased purified protein (red: mGM-CSF produced through gene transfer, black: purchased mGM-CSF protein).
Introduction Lung cancer is the leading cause of cancer death worldwide with over 70% of patients presenting with incurable disease and few effective treatments. We previously demonstrated that mesenchymal stem cells transduced to express TNF-related apoptosis inducing ligand (TRAIL), will home to and induce apoptosis of tumour cells in vitro and reduce tumour growth in multiple in vivo models. A key unknown of cellular therapy is the location and duration of cells following intravenous delivery.
111
Indium-oxine is established for lymphocyte tracking but it has low sensitivity and is toxic to cells.
89
Zirconium-oxine is a novel PET tracer which has better sensitivity and lower toxicity. Our study aimed to label MSCTRAIL with 89 Zr with the aim of tracking cells in patients enrolled in the TACTICAL trial -an early phase trial delivering MSCTRAIL to patients with metastatic lung adenocarcinoma. Methods MSC-TRAIL cells were incubated with multiple doses of 89 Zr-oxine and label retention measured using a gamma counter. Cells were assessed for cell viability using cell proliferation assays, TRAIL expression was determined using flow cytometry and ELISA and apoptosis was determined using coculture experiments with luciferase expressing cancer cell lines and bioluminescent readout. DNA damage and cellular stress was assessed using western blotting. To determine whether radiolabelled cells could be detected in vivo, 2 × 10 5 89 ZrOxine MSC-TRAIL cells were delivered intravenously and imaging was performed at multiple time points (Mediso PET-CT, AMI-X). Results
Zr-oxine labelling at clinically relevant doses did not affect cell proliferation and therapeutic efficacy was maintained in co-culture experiments. There was no evidence of DNA damage and cell stress response and cellular phenotype was maintained. CT/PET imaging after labelling and delivery of the cells into mice showed good correlation with bioluminescent signal confirming its use a high sensitivity tracking tool. Rationale There is increasing evidence of a link between abnormalities in the myeloid cell lineage and pulmonary arterial hypertension (PAH). Heterozygous mutations in the gene encoding the bone morphogenetic protein type 2 receptor (BMPR2) are the most common genetic cause of PAH. We sought to characterise the impact of the genetic loss/reduction of BMPR2 function in the myeloid lineage in mice and humans, and whether this altered susceptibility to PAH. Methods Mx1-cre mice were crossed with bmpr2 flox/flox mice. At approximately 8 weeks of age cre-recombinase was induced with polyinosinic-polycytidylic acid (Poly I:C). Control mice (bmpr2 flox/flox mice with no cre) were also induced with Poly I:C. At approximately 16 weeks post-induction mice underwent right-heart catheterisation, exsanguination and tissue was removed for analysis. The spleens were weighed and histology was performed on the femurs. Mouse data are presented as mean ±SEM. In a large cohort of PAH patients with (n=160) and without (n=831) BMPR2 mutations blood count indices were analysed. Data presented as median [IQR] . (8.8 [7.3-10.4] vs. 8.11 [6.77-9.61 
]).
Conclusions we have identified a role for bmpr2 in the differentiation of the mouse myeloid lineage, which was also confirmed in PAH patients with BMPR2 mutations. BMPR2 appears particularly important in the differentiation of megakaryocyte-erythrocyte lineage.
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